# Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

> **NCT02318082** · PHASE1 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 21 (actual)

## Conditions studied

- Chronic Versus Graft Host Disease

## Interventions

- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT02318082
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2017-10
- **Final completion:** 2020-04-22
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318082, "Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02318082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*